SG10201912545PA - T cell redirecting bispecific antibodies for the treatment of egfr positive cancers - Google Patents
T cell redirecting bispecific antibodies for the treatment of egfr positive cancersInfo
- Publication number
- SG10201912545PA SG10201912545PA SG10201912545PA SG10201912545PA SG10201912545PA SG 10201912545P A SG10201912545P A SG 10201912545PA SG 10201912545P A SG10201912545P A SG 10201912545PA SG 10201912545P A SG10201912545P A SG 10201912545PA SG 10201912545P A SG10201912545P A SG 10201912545PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- bispecific antibodies
- positive cancers
- egfr positive
- cell redirecting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17167709 | 2017-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912545PA true SG10201912545PA (en) | 2020-02-27 |
Family
ID=58632245
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912545PA SG10201912545PA (en) | 2017-04-24 | 2018-04-24 | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
| SG11201909498X SG11201909498XA (en) | 2017-04-24 | 2018-04-24 | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909498X SG11201909498XA (en) | 2017-04-24 | 2018-04-24 | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230159661A1 (en) |
| EP (1) | EP3615571A1 (en) |
| JP (1) | JP2020517659A (en) |
| KR (1) | KR20200002886A (en) |
| CN (1) | CN110831968A (en) |
| AU (1) | AU2018259039A1 (en) |
| CA (1) | CA3060190A1 (en) |
| EA (1) | EA201992143A1 (en) |
| MX (1) | MX2019012606A (en) |
| SG (2) | SG10201912545PA (en) |
| WO (1) | WO2018197502A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230067182A1 (en) * | 2019-11-29 | 2023-03-02 | Boe Technology Group Co., Ltd. | Data Processing Device and Method, and Computer Readable Storage Medium |
| WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| WO2022178040A1 (en) * | 2021-02-16 | 2022-08-25 | City Of Hope | Truncated domain iv egfr and uses thereof |
| WO2023183766A1 (en) * | 2022-03-20 | 2023-09-28 | Abcellera Biologics Inc. | Anti-cd3 antibodies and t-cell engagers and methods of use |
| WO2023192514A1 (en) * | 2022-03-30 | 2023-10-05 | Pinetree Therapeutics, Inc. | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
| CN114621351B (en) * | 2022-04-27 | 2023-01-03 | 华羊生物技术股份有限公司 | Multispecific antibodies and their use to treat cancer |
| WO2024030341A1 (en) * | 2022-07-30 | 2024-02-08 | Pinetree Therapeutics, Inc. | Compositions for targeted lysosomal degradaton and methods of use thereof |
| CN117305248A (en) * | 2022-09-09 | 2023-12-29 | 复星凯特生物科技有限公司 | Bispecific chimeric antigen receptor for resisting EGFR and cMet and application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119566A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| US10329350B2 (en) * | 2012-12-26 | 2019-06-25 | Industrial Technology Research Institute | Method for producing a multivalent fab fragment with collagen-like peptide |
| KR20150122203A (en) * | 2013-02-26 | 2015-10-30 | 로슈 글리카트 아게 | Bispecific t cell activating antigen binding molecules |
| BR112015026143A2 (en) * | 2013-04-19 | 2017-10-17 | Covagen Ag | Bispecific and nucleic acid ligand molecules, vector, host cell or non-human host, and pharmaceutical composition |
| CN104341504B (en) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | Bispecific antibody |
| NZ720161A (en) * | 2013-11-04 | 2022-07-29 | Ichnos Sciences SA | Production of t cell retargeting hetero-dimeric immunoglobulins |
| MA40894A (en) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES |
| CN104774268B (en) * | 2015-01-21 | 2018-09-28 | 武汉友芝友生物制药有限公司 | The structure of bispecific antibody EGFR × CD3 a kind of and application |
-
2018
- 2018-04-24 EP EP18721725.2A patent/EP3615571A1/en not_active Withdrawn
- 2018-04-24 WO PCT/EP2018/060488 patent/WO2018197502A1/en unknown
- 2018-04-24 SG SG10201912545PA patent/SG10201912545PA/en unknown
- 2018-04-24 US US16/607,783 patent/US20230159661A1/en not_active Abandoned
- 2018-04-24 SG SG11201909498X patent/SG11201909498XA/en unknown
- 2018-04-24 AU AU2018259039A patent/AU2018259039A1/en not_active Abandoned
- 2018-04-24 CN CN201880027187.0A patent/CN110831968A/en active Pending
- 2018-04-24 JP JP2019557468A patent/JP2020517659A/en active Pending
- 2018-04-24 CA CA3060190A patent/CA3060190A1/en not_active Abandoned
- 2018-04-24 KR KR1020197032632A patent/KR20200002886A/en unknown
- 2018-04-24 MX MX2019012606A patent/MX2019012606A/en unknown
- 2018-04-24 EA EA201992143A patent/EA201992143A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020517659A (en) | 2020-06-18 |
| AU2018259039A1 (en) | 2019-11-07 |
| WO2018197502A1 (en) | 2018-11-01 |
| CA3060190A1 (en) | 2018-11-01 |
| KR20200002886A (en) | 2020-01-08 |
| MX2019012606A (en) | 2019-12-02 |
| US20230159661A1 (en) | 2023-05-25 |
| CN110831968A (en) | 2020-02-21 |
| EP3615571A1 (en) | 2020-03-04 |
| EA201992143A1 (en) | 2020-03-13 |
| SG11201909498XA (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245134A1 (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
| IL267803A (en) | Methods of treating cancer with anti-tim-3 antibodies | |
| IL267804A (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| IL279235A (en) | Dll3-cd3 bispecific antibodies | |
| SG10201912545PA (en) | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers | |
| PL3519437T3 (en) | Bispecific antibodies against p95her2 | |
| IL264674B1 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| IL276303A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| GB201721338D0 (en) | Anti-icos Antibodies | |
| IL268479A (en) | Anti-pd-1 antibodies for treatment of lung cancer | |
| EP3507307A4 (en) | Bispecific antibodies | |
| EP3645040A4 (en) | Use of anti-fam19a5 antibodies for treating cancers | |
| IL277861A (en) | Axl-specific antibodies for cancer treatment | |
| EP3383497A4 (en) | Novel antibodies for the treatment of cancers | |
| TWI560201B (en) | Bi-specific antibodies for treating cancer | |
| ZA202004908B (en) | Bispecific antibody | |
| IL274766A (en) | Humanized anti-liv1 antibodies for the treatment of breast cancer | |
| SG11202011268VA (en) | Monospecific and multispecific anti-tmeff2 antibodies and there uses | |
| EP3644062C0 (en) | Method for predicting esophagus cancer response to anti-erbb3 antibody treatment | |
| IL282355A (en) | Exosome-targeting bispecific antibodies | |
| ZA201905711B (en) | Anti-pd-l1-anti-tim-3 bispecific antibodies | |
| SG11202008513WA (en) | De-immunised anti-erbb3 antibodies | |
| LT3317300T (en) | Bispecific antibodies for use in cancer immunotherapy | |
| EP3728311A4 (en) | Bispecific hiv-1-neutralizing antibodies | |
| IL280421A (en) | Cancer treatment with an antibody |